Rogojina A, Klesse L, Butler E, Kim J, Zhang H, Xiao X
iScience. 2023; 26(11):108171.
PMID: 37915590
PMC: 10616347.
DOI: 10.1016/j.isci.2023.108171.
LaCombe R, Cecchini A, Seibert M, Cornelison D
Biol Open. 2022; 11(10).
PMID: 36214254
PMC: 9581518.
DOI: 10.1242/bio.059352.
Ghilu S, Kurmasheva R, Houghton P
J Clin Med. 2021; 10(7).
PMID: 33916592
PMC: 8038510.
DOI: 10.3390/jcm10071504.
Yang J, Li Q, Noureen N, Fang Y, Kurmasheva R, Houghton P
Nucleic Acids Res. 2020; 49(D1):D1321-D1327.
PMID: 32810235
PMC: 7778893.
DOI: 10.1093/nar/gkaa698.
Houghton P, Kurmasheva R
Pharmacol Rev. 2019; 71(4):671-697.
PMID: 31558580
PMC: 6768308.
DOI: 10.1124/pr.118.016972.
Patient-derived xenograft models in musculoskeletal malignancies.
Lu W, Chao T, Ruiqi C, Juan S, Zhihong L
J Transl Med. 2018; 16(1):107.
PMID: 29688859
PMC: 5913806.
DOI: 10.1186/s12967-018-1487-6.
Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis.
Murphy B, Yin H, Maris J, Kolb E, Gorlick R, Reynolds C
Cancer Res. 2016; 76(19):5798-5809.
PMID: 27496711
PMC: 5050128.
DOI: 10.1158/0008-5472.CAN-16-0122.
FANCD2 is a potential therapeutic target and biomarker in alveolar rhabdomyosarcoma harboring the PAX3-FOXO1 fusion gene.
Singh M, Leasure J, Chronowski C, Geier B, Bondra K, Duan W
Clin Cancer Res. 2014; 20(14):3884-95.
PMID: 24787670
PMC: 4102646.
DOI: 10.1158/1078-0432.CCR-13-0556.
Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: utility and pitfalls.
Hinson A, Jones R, Crose L, Belyea B, Barr F, Linardic C
Front Oncol. 2013; 3:183.
PMID: 23882450
PMC: 3713458.
DOI: 10.3389/fonc.2013.00183.
Cell-based small-molecule compound screen identifies fenretinide as potential therapeutic for translocation-positive rhabdomyosarcoma.
Herrero Martin D, Boro A, Schafer B
PLoS One. 2013; 8(1):e55072.
PMID: 23372815
PMC: 3555977.
DOI: 10.1371/journal.pone.0055072.
Low Dose Histone Deacetylase Inhibitor, Depsipeptide (FR901228), Promotes Adenoviral Transduction in Human Rhabdomyosarcoma Cell Lines.
Navid F, Mischen B, Helman L
Sarcoma. 2008; 8(1):25-30.
PMID: 18521390
PMC: 2395599.
DOI: 10.1080/13577140410001679220.
Characterization and modulation of drug resistance of human paediatric rhabdomyosarcoma cell lines.
Cocker H, Pinkerton C, Kelland L
Br J Cancer. 2000; 83(3):338-45.
PMID: 10917549
PMC: 2374566.
DOI: 10.1054/bjoc.2000.1273.
Evaluation of a novel bis-naphthalimide anticancer agent, DMP 840, against human xenografts derived from adult, juvenile, and pediatric cancers.
Houghton P, Cheshire P, Hallman 3rd J, Gross J, McRipley R, Sun J
Cancer Chemother Pharmacol. 1994; 33(4):265-72.
PMID: 8281618
DOI: 10.1007/BF00685898.
Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts.
Friedman H, Houghton P, Schold S, Keir S, Bigner D
Cancer Chemother Pharmacol. 1994; 34(2):171-4.
PMID: 8194169
DOI: 10.1007/BF00685936.
Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.
Houghton P, Cheshire P, Hallman 2nd J, Lutz L, Friedman H, Danks M
Cancer Chemother Pharmacol. 1995; 36(5):393-403.
PMID: 7634381
DOI: 10.1007/BF00686188.
O6-Alkylguanine-DNA alkyltransferase activity correlates with the therapeutic response of human rhabdomyosarcoma xenografts to 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea.
Brent T, Houghton P, HOUGHTON J
Proc Natl Acad Sci U S A. 1985; 82(9):2985-9.
PMID: 3857628
PMC: 397691.
DOI: 10.1073/pnas.82.9.2985.
Evaluation of 3-(p-fluorophenyl)-L-alanyl-3-[m-bis-(2-chloroethyl) aminophenyl]-L-alanyl-L-methionine ethyl ester HCl (PTT.119) against xenografts of human rhabdomyosarcoma.
Houghton P, Tharp R, HOUGHTON J, HOLLAND J, BEKESI J
Cancer Chemother Pharmacol. 1988; 22(3):201-4.
PMID: 3409455
DOI: 10.1007/BF00273411.
Transplantability in nude mice of embryonic and other childhood tumours.
Rousseau-Merck M, BIGEL P, Mouly H, Flamant F, Zucker J, Wache A
Br J Cancer. 1985; 52(2):279-83.
PMID: 2992567
PMC: 1977113.
DOI: 10.1038/bjc.1985.189.
Evaluation of N-(5-indanylsulfonyl)-N'-(4-chlorophenyl)-urea against xenografts of pediatric rhabdomyosarcoma.
Houghton P, HOUGHTON J, Myers L, Cheshire P, Howbert J, GRINDEY G
Cancer Chemother Pharmacol. 1989; 25(2):84-8.
PMID: 2598403
DOI: 10.1007/BF00692344.
Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors.
Houghton P, Cheshire P, Myers L, Stewart C, Synold T, HOUGHTON J
Cancer Chemother Pharmacol. 1992; 31(3):229-39.
PMID: 1464161
DOI: 10.1007/BF00685553.